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Abstract This study was a detailed microscopic analysis of
the changes of vaginal microflora characteristics after applica-
tion of 0.03 mg estriol-lactobacilli combination on the vaginal
ecosystem in postmenopausal breast cancer (BC) survivors on
aromatase inhibitors (AI) with severe atrophic vaginitis. A
total of 16 BC women on AI applied daily one vaginal tablet
of Gynoflor® for 28 days followed by a maintenance therapy
of three tablets weekly for 8 weeks. During four follow up
visits a smear from the upper lateral vaginal wall was analysed
by phase contrast microscopy at 400 times magnification in
order to classify the lactobacillary grades(LBG), bacterial vag-
inosis (BV), aerobic vaginitis (AV), vulvovaginal candidosis
(VVC), proportional number of leukocytes and evidence of
parabasal cells and epitheliolysis. LBG improved from 81 %
LBG-III at entry to 88 % LBG-I&IIa after 2 weeks of initial
therapy, which further improved upon follow up (p<0.001).
Whereas BV was a rare event, AV was frequent and substan-
tially improved during treatment (p<0.01). While at entry
most patients had moderate or severe AV, after maintenance
therapy no patient except one had AV. The number of
leukocytes dropped dramatically from a score of 1.78±0.70
to 1.06±0.25 which was consistent till the end of the study
(p<0.01). Parabasal cells dropped from a score of 3.4±0.64 at
entry to 1.3±0.60 at the final visit (ptrend<0.01). Starting from a
low rate ofCandida colonisation of 2/14 (14%), a sudden rise to
7/16 (44%) occurred after 2 weeks, to return back to base levels
at susequent visits. The vaginal use of ultra-low dose estriol and
lactobacilli results in rapid and enduring improvement of all
markers of the vaginal microflora and epithelial vaginal cell
quality in women with breast cancer on AI with dyspareunia.
Candida may develop soon after its use, but rapidly disappears
again upon their prolonged use. Due to its excellent safety pro-
files and clinical efficacy we recommend this product as first
choice in women on AI with severe dyspareunia.
Introduction
A healthy vaginal ecosystem depends on a normal flora main-
ly consisting of Lactobacillus spp., a sufficient estrogen-
dependent maturation of the vaginal epithelium and an intact
local immunity [1–4]. Estrogen deprivation therapy installed
in hormone receptor positive breast cancer women prolongs
survival [5], but invariably leads to symptomatic vaginal atro-
phy or even aerobic vaginitis in both pre- and post-
menopausal women. The most common symptoms of vaginal
atrophy include dryness, dyspareunia, vaginal burning, dis-
charge and pain. These symptoms are paralleled by cytologi-
cal changes which, in a vaginal smear, manifest as a shift from
superficial cell towards parabasal and intermediate cells [6].
Atrophy of vulva, introitus and vagina can be especially prob-
lematic for women who want to stay sexually active but ex-
perience pain during sexual intercourse due to dryness and
atrophic changes [7–9], affecting sexual quality [10].
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Epithelial atrophy of the vagina can be treated by the
oral or vaginal administration of estriol, but according to
the Consensus Statement on Menopausal Hormone
Therapy, local therapy with low-dose estrogen is preferred
for women whose symptoms are limited to vaginal dry-
ness or associated discomfort with intercourse [11].
However, estrogen is readily absorbed through the vaginal
wall [10], leading to similar systemic effects as would be
produced by oral therapy with a 10–20 fold greater dose
[12]. Fortunately, only very small dosages are needed to
treat vaginal symptoms, and low-potency estrogens like
estriol (E3) can readily be used with only limited systemic
effects in spite of absorption [10].
Gynoflor is a well-established medicinal product contain-
ing 100 million viable Lactobacillus acidophilus KS400 and a
ultra low dose of 30 μg E3. It has been introduced to promote
the proliferation and maturation of the vaginal epithelium and
to enhance the restoration of the vaginal ecosystem [13–16].
In a double-blind, placebo-controlled study Jaisamrarn
et al. [17] demonstrated excellent short-term and long-term
efficacy of Gynoflor® in menopausal women with symptom-
atic atrophic vaginitis. In an ambitious pharmacokinetic (PK)
study we assessed circulating systemic estrogens in breast
cancer (BC) patients on a non-steroidal aromatase inhibitor
(NSAI) after insertion of Gynoflor® in vagina affected by
severe atrophy [5]. Compared with baseline, serum estrone
(E1) and estradiol (E2) did not increase in any of the women
at any time following vaginal application. Serum E3 transient-
ly increased after the first application in 15 of 16 women, with
a maximum of 168 pg/ml 2–3 hours post-insertion. After
4 weeks, serum E3 was only slightly increased in eight of 16
women with a maximum of 44 pg/ml, without causing any
relevant change in serum LH (luteinising hormone), FSH (fol-
licle stimulating hormone) and SHBG (sex hormone binding
globulin) concentrations. It was concluded that local vaginal
therapy with ultra-low-dose 0.03 mg estriol-lactobacilli com-
bination (Gynoflor®) in postmenopausal BC survivors on aro-
matase inhibitors (AIs) reporting atrophic vaginitis is a phar-
macologically safe treatment with a positive impact on quality
of life and sexual activity [5].
In this contribution we analyse the changes of vaginal
microflora characteristics in detail in an effort to explain
the excellent efficacy of ultra-low-dose 0.03 mg estriol-
lactobacilli combination (Gynoflor®) on the vaginal eco-
system in these women and normalisation in postmeno-
pausal BC survivors on AIs with severe atrophic
vaginitis.
Subjects and methods
The safety data and main results of this Phase I pharma-
cokinetic (PK) study (EudraCT No: 2010-022007-22)
have been reported earlier [5]. Sixteen women on NSAI
with severe vaginal atrophy (Entry visit, E) applied daily
one vaginal tablet of Gynoflor® for 28 days followed by a
maintenance therapy of three tablets weekly for 8 weeks
and were seen at four follow up visits (C1-C4), where a
smear was taken from the upper lateral vaginal wall after
introduction of a water lubricated, small size speculum.
pH was measured and the smear was numbered and air-
dried. Before sending the smears to the central lab
(Femicare, Tienen, Belgium), the slides were renumbered
according to a computer-generated random table, in order
to prevent possible recognition of the microscopist of the
nature or order of the visit on which the slide was taken.
This code was broken only after complete finalization of
the patient follow up data and after the database was
locked.
Microscopy was done in a systematic way after re-
hydration with a droplet of saline by using a Leica phase
contrast microscope at 400 times magnification (DC 1000,
Warburg, Germany) according to the classification system
published elsewhere [18]. In brief, lactobacillary grades
(LBG) were classified and bacterial vaginosis (BV) flora
was diagnosed on the basis of the typical granular micro-
flora. Full BV was defined when the BV flora was ob-
served all over the smear with presence of more than
20 % clue-cells or 'partial BV' if there were less than
20 % of clue cells with only areas with streaks of BV-like
bacteria mixed with other morphotypes [19]. Aerobic vag-
initis (AV) flora was defined and classified according to the
presence of small bacilli exclusively or containing cocci in
pairs or chains. LBGs, and presence of parabasal cells and
leucocytes (see below) were added to the final AV score
[20]. Evaluation of vulvovaginal candidosis (VVC) was
made when unequivocal pseudohyphae and/or blastopores
(‘snowman’ shape) were detected on the smears (Fig. 1a).
In cases where the blastospores or hyphae were damaged
or atypical, they were designated as 'possible Candida'
(Fig. 1b). Leucocytes were quantified and evaluated if a
granular or swallowed nuclei were present, determining
their toxic form. Quantification of leukocytes was done
by counting their number per high power field, and if more
than ten (score 2 or more), by counting them as a ratio to
the number of epithelial cells present: <10 per epithelial
cell is scored as 2, more than 10 per epithelial cell as 3,
and full field of leucocytes as 4. Presence of mucous cer-
vicitis was considered if leucocytes were numerous and
following a layer pattern. Evidence of cytolysis of epithe-
lial cells was detected by the presence of cytoplasm re-
mains and bare nuclei, with classification in slight or se-
vere cases according to the extension on the smears.
Fisher's exact was used to determine statistical significance
between groups. For normally distributed continuous vari-
ables Student's t-test was used.
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Results
Gynoflor® successfully decreased the vaginal pH, and im-
proved the majority of signs and symptoms of vaginal atrophy
as well as the vaginal maturity index (VMI), lactobacillary
grades and the presence of moderate to severe AV [5]. These
improvements mostly appeared immediately during initial
therapy and improved further under maintenance therapy.
At entry the majority of patients (81 %) had the most severe
form of abnormal vaginal flora (LBG III), while the remaining
had LBG IIb. Already after 2 weeks of initial therapy most
patients presented with slightly disturbed (LBG IIa, 63 %) or
normal (LBG I, 25 %) vaginal flora patterns, both considered
normal, and no severely disturbed flora (LBG III) (Fig. 2).
Further improvements were observed at the end of the main-
tenance therapy, at which point the majority of patients had
normal (LBG I, 69 %) or slightly disturbed (LBG IIa, 25 %)
vaginal flora. Changes in LBG from entry to all control visits
as well as the further change observed during the maintenance
therapy were statistically significant (p<0.001) (Figs. 2 and 3).
Fig. 1 Rehydrated air-dried microscopy pictures of Candida (a-c) and
possible Candida (d-f). a Candida pseudo-mycelium is visualized
(circle) in a background of lactobacillary grade (LBG) IIB, normal
superficial cells, and no inflammation. b Beginning Candida pseudo-
mycelium (large circle) and blastospores (small circle) are visualized in
a background of LBG IIB, normal superficial cells, and no inflammation.
c Multiple blastospores (both circles) suggestive of non-albicans
Candida in a background of LBG IIA, normal superficial cells, and no
inflammation. In pictures d, e and f structures are encountered that
somewhat resemble Candida organelles, but insufficiently
pathognomonic to ascertain a diagnosis. In such cases extra cultures or
PCR may be required to confirm the diagnosis. In (d) the background is
LBG 1, in (e) LBG III, and in (f) LBG I, small lactobacillary
morphotypes. In all pictures maturation index is high and there is no
inflammation
Fig. 2 Change in flora
characteristics of the vaginal
microflora, inflammation and in
quality of the vaginal epithelial
cells at entry and during four
follow up visits of 16 BC patients
with aromatase inhibitor intake
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Although there was a non-significant trend of diminishing
BV flora towards the end of the study, the BV score showed
no significant variations over time, and its presence was a
rather rare event with two to four patients expressing BV flora
at entry or control visits.
On the contrary, the AV score substantially improved dur-
ing treatment. At entry most patients had moderate (31 %) or
severe (50 %) AV, while after initial therapy most patients
presented without (62.5 %) or with only light AV (37.5 %)
flora (p<0.01). After maintenance therapy no patient except
for one (94 %) had AV. The improvements in AV score from
entry to all respective control visits and further improvement
have been observed after maintenance therapy and they were
statistically significant. Remarkably, the inflammatory com-
ponent, as assessed by the proportional number of leukocytes
present, dropped dramatically from a score of 1.78±0.70 to
1.06±0.25 which was consistent till the end of the study.
Heavy (>10 leukocytes/epithelial cell) and moderate
leucocytosis (>10/high power field, but <10/epithelial cell)
were seen in two, respectively, in 7 of the 15 slides at entry
(one slide unreadable) but only two had moderate and none
severe leucocytosis at subsequent visits.
The presence of parabasal cells, a surrogate marker of vag-
inal maturity (also expressed by the VMI), and component of
the AV score, dropped dramatically and continuously from a
score of 3.4±0.64 at entry to 2.0±0.81 in V1, 1.6±0.72 at V2,
1.5±0.6 at V3 and 1.3±0.60 at the final visit (ptrend<0.01).
Finally, a surprising course of Candida presence became
evident. Starting from a low rate of unequivocal Candida
colonisation of 2/14 (14 %), a sudden rise to 7/16 (44 %) at
Fig. 3 In patient 1, severe atrophywith lactobacillary grade (LBG) III, 50
% intermediate and 20 % parabasal epithelial cells are visualized at entry
(a). The numerous red blood cells (RBC) indicated atrophic bleeding.
After 1 week (b) and 12 weeks (c) of treatment the LBG improved
dramatically to LBG I, no RBC, no inflammation and high numbers of
superficial cells (above 80%). In patient 2, lactobacillary grade (LBG) III,
anaerobic microflora, 60 % intermediate and 20 % parabasal epithelial
cells were seen at entry (d). After 1 week in patient 1, severe atrophy with
lactobacillary grade (LBG) III, 50 % intermediate and 20 % parabasal
epithelial cells are visualized at entry (a). The numerous red blood cells
(RBC) indicated atrophic bleeding. After 1 week and 12 weeks of
treatment the LBG has improved dramatically to LBG I, no RBC, no
inflammation and high numbers of superficial cells (above 80 %). After
12 weeks of treatment the LBG has improved dramatically to LBG IIb
and LBG I (e and f, respectively), and in both instances there was no
inflammation and high numbers of superficial cells (>80 % and >90 %,
respectively). In patient 3, severe atrophy was diagnosed with
lactobacillary grade (LBG) III, 25 % intermediate and 60 % parabasal
epithelial cells at initial visit (g). Treatment resulted in LBG IIA after one
week and LBG I after 12 weeks of treatment, respectively, and above 80
% superficial cells in both instances. Remarkably in the smear taken after
one week of treatment, a sperm cell was encountered (arrow, h)
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C1 occurred, to return back to base levels of 19 %, 19 % and
13 % in the subsequent visits, respectively. This peak at C1
shows a significantly higher rate of unequivocal Candida than
in the other visits (p=0.035), and when the 'possible' Candida
is taken into consideration, the difference is even more pro-
nounced (10/16, 63% at V1 vs 16/53, 25%, p=0.008). In four
of seven women with Candida at C1, colonisation persisted at
one (n=1), two (n=2) or all three subsequent visits (n=1).
Nevertheless, only one patient was symptomatic enough to
take treatment, while the others did not require or receive
any antimycotic treatment.
Discussion
All estrogens are contra-indicated in hormone receptor posi-
tive BCwomen, however, it is necessary to reflect on safety of
any possible treatment regimen for vaginal atrophy. The daily
vaginal application of ultra-low dose 0.03 mg E3 in postmen-
opausal women results only in a small and transient increase
in serum E3, but serum levels of E1, E2, FSH, LH and SHBG
are not influenced leading to the conclusion this therapy could
be safe even in hormone sensitive BC patients [5, 13, 21].
Furthermore, the proliferation of the vaginal epithelium dur-
ing repeated daily therapy with 0.03 mg E3 and lactobacilli in
BC women with vaginal atrophy reduces the absorption of E3
even further, in so far that after an initial therapy of 12 days the
E3 serum levels did not increase at all in most of the women
on maintenance therapy [5]. The typical side effects of estro-
gen (water retention, feeling of tension in the breasts,
mastalgia, increase in weight, migraine headaches, visual dis-
turbances, nausea, increase in blood pressure, bleeding from
the uterus, etc.) nor endometrium proliferation were reported
for Gynoflor® and ultra-low dose vaginal E3 in general [10,
13, 17, 21–25]. The Lactobacillus acidophilus strain contained
in Gynoflor® is of human origin and has been shown in-vitro
to possess the key beneficial properties for vaginal use. The
strain produces lactic acid hydrogen peroxide, and bacteriocin
and adheres well to epithelial cells, and thus significantly in-
hibits the growth and adherence of vaginal pathogens [16].
In the present study we could demonstrate that the im-
provement of the VMI coincides with the improvement of
the vaginal bacterial microflora. This transition occurs imme-
diately after start of therapy and is well maintained during
maintenance therapy with three vaginal tablets weekly. At
entry an increased number of parabasal cells (PBC) were pres-
ent in almost all women, as markers of severe atrophy. Upon
treatment, however, the mean number of PBC was strongly
reduced, and the mean VMI was 70 % or more for the whole
duration of the study. Reciprocally, LBG promptly improved
to normal flora patterns in more than 80 % of women after
initiation of therapy, and even to more than 90 % of women in
the maintenance phases. Even though lactobacilli were absent
(LBG III) in most patients at entry, BV was only present in
14 % of them, indicating most subjects with disrupted flora
have AV rather than BV in this patient group. Remarkably,
even with improving LBGs, the rate of BV hardly changed
over time, and at control in two even a slight increase was
seen. The latter can be related to resumed or increased sexual
activity, as BV is known to be associated with the level of
sexual intercourse. Unexpectedly, the Candida colonization
rate rose three-fold immediately after initiation of therapy to
44 % of women, but declined to baseline rates after.
Remarkably this decline occurred without treatment, as only
one patient used antifungal medication. This observation
seems to indicate that most of these findings are indicative
of asymptomatic colonisation rather than symptomatic VVC.
Still we would recommend to routinely check for VVC in
patients treated for atrophic vaginitis, as the rate of Candida
was higher than expected, especially in the first weeks after
initiation of treatment with Gynoflor®. About the reason why
Candida colonisation increased at first and then declined
again, we can only speculate. It is known that a sudden change
in flora, with improvement of the vaginal epithelium and
LBGs due to treatment of BV, for instance, after treatment
with metronidazole, can coincide with the occurrence of
symptomatic VVC and that Candida is found more often in
lactobacillus dominant flora. The subsequent decline after this
initial peak, however, can possibly be ascribed to the protec-
tive effect of Gynoflor®, as its L. acidophilus is known for its
beneficial properties against pathogens [16].
Finally, the treatment with low E3 combined with
lactobacilli had a profound and unexpected effect on vaginal
inflammation. Probably this reduction of immune competent
cells and leukocytes is a favourable finding not only for symp-
tomatic women like BC patients or other menopausal women
with vaginal atrophy, but could also turn out to be beneficial
for pregnant women with disrupted flora and at risk of preterm
delivery. Studies testing the potential benefits of such probi-
otic products in pregnancy are urgently needed.
Of course, we realize that our conclusions are based on a
small number of patients and need to be confirmed in larger
series. However, as the data were retrieved from a phase 1
safety trial in breast cancer patients, higher numbers were
not feasible in this setting. Also as a compensation for the
small numbers, microscopic studies were done in great detail
(according to the Femicare protocol [18]), allowing minimal
changes to be detectedmore readily. Furthermore, the findings
were so dramatic and universal that even in low numbers they
were clear and outstanding. That larger numbers would sig-
nificantly change the conclusions therefore seems unlikely.
One could argue that cultures and/or molecular microbioma
research could have brought a broader insight in the changes
brought along in the vaginal microflora. However, positive
cultures or PCR findings would still not reflect the health
status of the flora as good as microscopy does [26]. An
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exception could be the increased detection rate of Candida
organisms by use of extra techniques, but in that case most
likely only representing asymptomatic colonisation would be
detected.
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